J M Kirkwood

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
    J M Kirkwood
    Division of Hematology Oncology and Department of Pathology, Department of Medicine, University of Pittsburgh Cancer Institute Melanoma Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 19:2370-80. 2001
  2. ncbi Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
    H M Zarour
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 97:400-5. 2000
  3. ncbi High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
    J M Kirkwood
    Department of Pathology, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 18:2444-58. 2000
  4. ncbi High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696
    J M Kirkwood
    University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute Melanoma Center, Department of Medicine, Division of Hematology Oncology, Pittsburgh, PA, USA
    J Clin Oncol 19:1430-6. 2001
  5. ncbi gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells
    L S Kierstead
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Br J Cancer 85:1738-45. 2001
  6. ncbi IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro
    L Vujanovic
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Gene Ther 13:798-805. 2006
  7. ncbi Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma
    S S Agarwala
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Oncologist 5:144-51. 2000
  8. ncbi SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas
    S J Moschos
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Oncogene 26:4216-25. 2007
  9. ncbi Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690
    U N M Rao
    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 20:2053-7. 2002
  10. ncbi Targeted therapy for malignant melanoma
    C K Brown
    Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, 200 Lothrop Street, N-758 MUH, Pittsburgh, PA 15213-2582, USA
    Curr Oncol Rep 3:344-52. 2001

Collaborators

Detail Information

Publications11

  1. ncbi High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801
    J M Kirkwood
    Division of Hematology Oncology and Department of Pathology, Department of Medicine, University of Pittsburgh Cancer Institute Melanoma Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2582, USA
    J Clin Oncol 19:2370-80. 2001
    ....
  2. ncbi Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
    H M Zarour
    Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 97:400-5. 2000
    ..Taken together, these data support the use of this Melan-A/MART-1 DR4-restricted melanoma epitope in future immunotherapeutic trials designed to generate, augment, and quantitate specific CD4(+) T cell responses against melanoma in vivo...
  3. ncbi High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190
    J M Kirkwood
    Department of Pathology, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 18:2444-58. 2000
    ..Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNalpha2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and overall survival (RFS and OS) benefit compared with observation (Obs)...
  4. ncbi High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696
    J M Kirkwood
    University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute Melanoma Center, Department of Medicine, Division of Hematology Oncology, Pittsburgh, PA, USA
    J Clin Oncol 19:1430-6. 2001
    ....
  5. ncbi gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells
    L S Kierstead
    Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA
    Br J Cancer 85:1738-45. 2001
    ..Based on these data, these epitopes may serve as potent vaccine components to promote clinically-relevant Th1-type CD4+ T cell effector function in situ...
  6. ncbi IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro
    L Vujanovic
    Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Gene Ther 13:798-805. 2006
    ..Based on these results, we believe this modality may prove clinically useful as a vaccine platform to promote the recovery of tumor antigen-specific, Th1-type CD4(+) T-cell responses in patients with cancer...
  7. ncbi Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma
    S S Agarwala
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
    Oncologist 5:144-51. 2000
    ..Therefore, TMZ is actively being investigated for the treatment and prevention of brain metastases in melanoma patients. TMZ may become an important part of treatment regimens for advanced metastatic melanoma...
  8. ncbi SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas
    S J Moschos
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213 1863, USA
    Oncogene 26:4216-25. 2007
    ....
  9. ncbi Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690
    U N M Rao
    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, PA 15213 2582, USA
    J Clin Oncol 20:2053-7. 2002
    ....
  10. ncbi Targeted therapy for malignant melanoma
    C K Brown
    Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, 200 Lothrop Street, N-758 MUH, Pittsburgh, PA 15213-2582, USA
    Curr Oncol Rep 3:344-52. 2001
    ..This work has furthered our understanding of the basis of malignancy, as well as the development of novel strategies aimed at targeting aberrant growth in melanoma...
  11. ncbi Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
    H A Tawbi
    Melanoma and Skin Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
    Br J Cancer 105:773-7. 2011
    ..Depletion of MGMT can be achieved using O6-meG pseudosubstrates. Herein, we report the first phase I experience of the novel O6-meG pseudosubstrate lomeguatrib, combined with dacarbazine...